- AlloSure differentiates "Active Rejection" from "Non Rejection"
- Assay has sensitivity of 59% and specificity of 85% at a 1% threshold
- AlloSure provides PPV of 60% at a 1% threshold and 85% at a 3% threshold
- AlloSure provides NPV of 84% at a 1% threshold and 80% at a 3% threshold
For more information, please visit: www.CareDx.com. Forward Looking Statements This press release contains forward-looking statements including, but not limited to our business, research, development and commercialization efforts and anticipated future financial results. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including the continued successful development and planned commercialization of AlloSure, that are described in our filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2015 filed by us with the SEC on March 29, 2016 and the Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2016 filed by us with the SEC on November 15, 2016. Any of these may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
Investor Relations ContactJamar Ismail, Vice PresidentWestwicke Partners, LLC T: +1 415-513-1282E: firstname.lastname@example.org